Samir Ounzain, CEO of science start-up HAYA Therapeutics, talks about the limits of entrepreneurship in Switzerland, entering the US market and how his therapy for heart disease could change the world of medicine. Founded in 2019, HAYA Therapeutics aims to pioneer an approach to treating disease by turning sick cells back into healthy ones. The start-up is currently developing a very specific therapy for heart failure and is about to begin the three challenging phases of clinical trials. If successful, the novel approach could be used to treat a wide range of common, chronic, and age-related diseases. HAYA Therapeutics has so far raised around $90 million (CHF72 million) and benefitted from investor confidence, but the next steps to success could be challenging, including gaining market authorisation, CEO and co-founder Samir Ounzain tells Swissinfo from his headquarters in Lausanne. Swissinfo: You are British, you studied in the United Kingdom but you decided to set your start-up ...
Full story here
Are you the author?
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC).
Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
Previous post
See more for 3.) Swissinfo Business and Economy
Next post
Tags:
Featured,
newsletter
